Table4.

Examples of FGFR inhibitors in clinical trials

Drug	Target	Phase	Study population	Clinicaltrials.gov
Multikinase FGFR inhibitors
Dovitinib	VEGFR, FGFR, PDGFR, KIT, FLT3, RET, NTRK	2	FGFR1 amplified NSCLC	NCT01861197
Pazopanib	VEGFR, FGFR, PDGFR, KIT	2	Solid tumors with FGFR2 alterations	NCT02450136
Lucitanib	VEGFR, FGFR, PDGFR	2	Genotypically selected NSCLC/SCLC	NCT02109016
Nintedanib	VEGFR, FGFR, PDGFR, RET, FLT3	2	Genotypically selected NSCLC	NCT02299141
			FGFR biomarker analysis in LUSC	NCT01948141
Selective FGFR inhibitors
BAY1163877	FGFR1-3	1/2	FGF/FGFR-aberrant solid tumors or MM	NCT02052778
TAS-120	FGFR1-4	1	Solid tumors	NCT01752920
ARQ087	FGFR1-4, mut FGFR2	1b	FGFR-aberrant solid tumors	NCT01752920
JNJ-42756493	FGFR1-4	1	Dose expansion LUSC, SCLC	NCT01703481
FP-1039 (GSK3052230)	FGF-ligand trap (anti-FGFR1)	1	Solid tumors with aberrant FGF signaling	NCT01868022